Beam Therapeutics Inc. - Common Stock — 현금 흐름 (NASDAQ:BEAM)

Financials

영업활동으로 인한 현금 -95.74 M-66.27 M22.53 M-149.19 M-347.25 M-345.1 M -369.73 M 투자 활동으로 인한 현금 -100.12 M-294.14 M-461.34 M71.84 M185.01 M-121.44 M 28.92 M 재무활동으로 인한 현금 322.32 M756.14 M111.59 M276.45 M7.74 M478.05 M 101.28 M 잉여 현금 흐름 -95.74 M-66.27 M22.53 M-149.19 M-347.25 M-360.05 M -383.84 M

Beam Therapeutics Inc. - Common Stock

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

BEAM

Financials

Beam Therapeutics Inc. - Common Stock

뉴스

Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

These Are The Upcoming Catalysts For Crispr Therapeutics Stock (NASDAQ:CRSP)

Beam Therapeutics Inc. (BEAM) Presents at ATS 2026 International Conference - Slideshow (NASDAQ:BEAM) 2026-05-20

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

Three Best Genomics Stocks for Your Portfolio in 2026

Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency - Slideshow (NASDAQ:BEAM) 2026-03-27

BEAM Eyes Global Expansion of AATD Study After Strong Early Data

Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript

Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?

화이자 협력 소식에 힘입어, Beam Therapeutics, H.C. Wainwright ’매수’ 의견 유지